Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Stock Information for Agenus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agenus Inc.

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Agenus to Host First 2026 Stakeholder Webcast
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.